# PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT5629924

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
SEQUENCE:	2	

## **CONVEYING PARTY DATA**

Name	Execution Date
REDOX SRL	05/17/2016

#### **RECEIVING PARTY DATA**

Name:	TONIX PHARMACEUTICALS, INC.	
Street Address:	509 MADISON AVENUE, SUITE 306	
City:	NEW YORK	
State/Country:	NEW YORK	
Postal Code:	10022	

## **PROPERTY NUMBERS Total: 1**

Property Type	Number
Application Number:	16518338

#### **CORRESPONDENCE DATA**

Fax Number:

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Email: maria.marley@hglaw.com
Correspondent Name: HALEY GUILIANO LLP

Address Line 1: 75 BROAD STREET, SUITE 1000 Address Line 4: NEW YORK, NEW YORK 10004

ATTORNEY DOCKET NUMBER:	104545-0008-305
NAME OF SUBMITTER:	MARIA MARLEY
SIGNATURE:	/MARIA MARLEY/
DATE SIGNED:	07/22/2019

## **Total Attachments: 5**

source=104545-0008-305-REDOX-TPI#page1.tif source=104545-0008-305-REDOX-TPI#page2.tif source=104545-0008-305-REDOX-TPI#page3.tif source=104545-0008-305-REDOX-TPI#page4.tif source=104545-0008-305-REDOX-TPI#page5.tif

PATENT 505583125 REEL: 049825 FRAME: 0623

## ASSIGNMENT

We, <u>REDOX srl</u>, known as <u>REDOX snc</u> prior to April 15, 2014, having an office and a place of business at <u>Viale Stucchi 62/26, 20900 Monza (MI)</u>, <u>Italy</u>, for good and valuable consideration, including consideration of one Euro (€1.00), receipt of which is hereby acknowledged, have assigned, sold and transferred to and do hereby assign, sell and transfer to <u>TONIX PHARMACEUTICALS</u>, <u>INC</u>, having an office and a place of business at <u>509 Madison Avenue</u>, <u>Suite 306</u>, <u>New York</u>, <u>NY 10022</u>, <u>United States of America</u>, its successors and assigns (1) the entire right, title and interest in the United States and in all countries throughout the world in and to any and all our inventions and discoveries disclosed in the following applications:

- (i) United States Provisional Application No. <u>62/052,238</u>, filed <u>September 18, 2014</u> and entitled "<u>Eutectic Formulations of Cyclobenzaprine Hydrochloride</u>"; and
- An International Patent Application that claims priority to application (i) above, (ii)filed under the Patent Cooperation Treaty on September 18, 2015 and assigned serial number PCT/US2015/051068 entitled "Eutectic Formulations of Cyclobenzaprine Hydrochloride", designating all PCT member states, including Albania (AL), Algeria (DZ), Angola (AO), Antigua & Barbuda (AG), Armenia (AM), Australia (AU), Austria (AT), Azerbaijan (AZ), Bahrain (BH), Barbados (BB), Belarus (BY), Belgium (BE), Belize (BZ), Benin (BJ), Bosnia and Herzegovina (BA), Botswana (BW), Brazil (BR), Bulgaria (BG), Brunei Darussalam (BN), Burkina Faso (BF), Cameroon (CM), Canada (CA), Central African Republic (CF), Chad (TD), Chile (CL), China (CN), Colombia (CO), Congo (CG), Costa Rica (CR), Côte d'Ivoire (CI), Croatia (HR), Cuba (CU), Cyprus (CY), Czech Republic (CZ), Democratic People's Republic of Korea (KP), Denmark (DK), Dominica (DM), Dominican Republic (DO), Ecuador (EC), Egypt (EG), El Salvador (SV), Equatorial Guinea (GQ), Estonia (EE), Finland (FI), France (FR), Gabon (GA), Gambia (GM), Georgia (GE), Germany (DE), Ghana (GH), Greece (GR), Grenada (GD), Guatemala (GT), Guinea (GN),

-1.

Guinea Bissau (GW), Honduras (HN), Hungary (HU), Iceland (IS), India (IN), Indonesia (ID), Ireland (IE), Islamic Republic of Iran (IR), Israel (IL), Italy (IT), Japan (JP), The Comoros (KM), Kazakhstan (KZ), Kenya (KE), Kyrgyzstan (KG), Lao People's Democratic Republic (LA), Latvia (LV), Lesotho (LS), Liberia (LR), Libyan Arab Jamahriya (LY), Liechtenstein (LI), Lithuania (LT), Luxembourg (LU), Madagascar (MG), former Yugoslav Republic of Macedonia (MK), Malawi (MW), Malaysia (MY), Mali (ML), Malta (MT) Mauritania (MR), Mexico (MX), Monaco (MC), Mongolia (MN), Montenegro (ME), Morocco (MA), Mozambique (MZ), Namibia (NA), Netherlands (NL), New Zealand (NZ), Nicaragua (NI), Niger (NE), Nigeria (NG), Norway (NO), Oman (OM), Panama (PA), Papua New Guinea (PG), Peru (PE), the Philippines (PH), Poland (PL), Portugal (PT), Qatar (QA), Republic of Korea (KR), Republic of Moldova (MD), Romania (RO), Russian Federation (RU), Rwanda (RW), Saint Lucia (LC), Saint Kitts and Nevis (KN), Saint Vincent and the Grenadines (VC), San Marino (SM), São Tomé and Príncipe (ST), Saudi Arabia (SA), Senegal (SN), Serbia (RS), Seychelles (SC), Sierra Leone (SL), Singapore (SG), Slovakia (SK), Slovenia (SI), South Africa (ZA), Spain (ES), Sri Lanka (LK), Sudan (SD), Swaziland (SZ), Sweden (SE), Switzerland (CH), Syrian Arab Republic (SY), Tajikistan (TJ), United Republic of Tanzania (TZ), Togo (TG), Thailand (TH), Trinidad and Tobago (TT), Tunisia (TN), Turkey (TR), Turkmenistan (TM), Uganda (UG), Ukraine (UA), United Arab Emirates (AE), United Kingdom (GB), United States of America (US), Uzbekistan (UZ), Viet Nam (VN), Zambia (ZM) and Zimbabwe (ZW);

including any applications and patents claiming priority therefrom, and any renewals, revivals, reissues, reexaminations, extensions, supplementary protection certificates, continuations and divisions thereof, and any substitute applications therefor; (2) the full and complete right to file patent applications in the name of <u>TONIX</u>

PHARMACEUTICALS, INC., its designee, or in our name at <u>TONIX</u>

PHARMACEUTICALS, INC. or its designee's election, on the aforesaid inventions, discoveries and applications in all countries of the world; (3) the entire right, title and interest in and to any Letters Patent that claims priority therefrom in the United States or

~2~

in any other country of the world and any renewals, revivals, reissues, reexaminations, supplementary protection certificates, and extensions of the same; and (4) the entire right, title and interest in all Convention and Treaty Rights of all kinds thereon, including without limitation all rights of priority in any country of the world, in and to the above inventions, discoveries and applications.

We hereby authorize and request the competent authorities to grant and to issue any and all such Letters Patent in the United States and throughout the world to <a href="Monix Pharmaceuticals">TONIX PHARMACEUTICALS</a>, INC. as the assignee of the entire right, title and interest therein, as fully and entirely as the same would have been held and enjoyed by us had this assignment, sale and transfer not been made.

We agree, at any time, upon the request of <u>TONIX</u>

<u>PHARMACEUTICALS, INC.</u> to execute and to deliver to <u>TONIX</u>

<u>PHARMACEUTICALS, INC.</u> any additional applications for patents for said inventions and discoveries, or any part or parts thereof, and any applications for patents of confirmation, registration and importation based on any Letters Patent issuing on said inventions, discoveries or applications, and divisions, continuations, renewals, revivals, reissues, reexaminations, extensions, supplementary protection certificates, and substitute applications thereof.

We further agree at any time to execute and to deliver upon request of TONIX PHARMACEUTICALS, INC, such additional documents, if any, as are necessary or desirable to secure patent protection on said inventions, discoveries and applications throughout all countries of the world, and otherwise to do the necessary to give full effect to and to perfect the rights of TONIX PHARMACEUTICALS, INC, under this Assignment, including the execution, delivery and procurement of any and all further documents evidencing this assignment, transfer and sale as may be necessary or desirable.

ASSIGNOR:	REDOX sri
	Name: Title:
	Date: 14/05/2016
WITNESSES:	
<u>A</u>	17/5/16
Name:	Date
<u> Sui Ga</u>	<u> </u>
Name:	Date

## ACKNOWLEDGEMENT OF ASSIGNEE:

I hereby acknowledge the foregoing executed Assignment on behalf of <u>TONIX</u> PHARMACEUTICALS, INC.

By: Ath Soleman Date: 5/23/16

Name: Title:

State of New York

On this 23 day of May, 2016, before me, the undersigned notary public, personally appeared Still Lederman, proved to me through satisfactory evidence of identification, which was NY Drivers Likewise, to be the person whose name is signed on the preceding or attached document in my presence.

Mary C. Dreathead Notary Public

My commission expires 9/4/10